

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT2628176

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	CHANGE OF NAME
CONVEYING PARTY DATA	
Name	Execution Date
ZHEJIANG BETA PHARMA INC.	08/29/2013
RECEIVING PARTY DATA	
Name:	BETTA PHARMACEUTICALS CO., LTD
Street Address:	589 HONGFENG RD., YUHANG
City:	HANGZHOU, ZHEJIANG
State/Country:	CHINA
Postal Code:	311100
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	13809836
CORRESPONDENCE DATA	
Fax Number:	(312)456-8435
Phone:	3124568400
Email:	chiipmail@gtlaw.com
<i>Correspondence will be sent via US Mail when the email attempt is unsuccessful.</i>	
Correspondent Name:	GREENBERG TRAUIG, LLP
Address Line 1:	77 WEST WACKER DRIVE
Address Line 2:	SUITE 3100
Address Line 4:	CHICAGO, ILLINOIS 60601
ATTORNEY DOCKET NUMBER:	147028.010113
NAME OF SUBMITTER:	WEISUN RAO, PH.D.
Signature:	/Weisun Rao/
Date:	11/25/2013

This document serves as an Oath/Declaration (37 CFR 1.63).

Total Attachments: 3

source=13809836 147028.010113#page1.tif

source=13809836 147028.010113#page2.tif

source=13809836 147028.010113#page3.tif

In the United States Patent and Trademark Office

Application No.: 13/809,836 Filing Date: January 11, 2013
First Named Inventor: Shaojing HU Attorney Docket No.: 147028.010113
Title of Application: Novel Fused Heterocyclic Derivatives Useful as c-Met Tyrosine Kinase Inhibitors

Commissioner for Patents
P.O. Box 1450
Alexandria, VA

Request to Change Co-Assignee Name


The co-assignee and co-owner of the present application — “ZHEJIANG BETA PHARMA INC.” — has changed its name to “BETTA PHARMACEUTICALS CO., LTD.” A declaration signed by its Vice President stating to the same effect is attached, along with a copy of the official notification of the name change in the Chinese language. Please kindly update the co-assignee information and provide us with an updated Notification of Recordation of Assignment Document or an Updated Filing Receipt to reflect the name change.

No fees are believed due. However, if there is any charge, please apply it to Deposit Account No. 50-2428, referring to attorney docket number 147028.010113.

Respectively submitted

Date:

Nov. 25, 2013


Weisun Rao, Ph.D., Reg. No. 68824
Attorney for the Applicants and Assignees
77 W. Wacker Drive, Suite 3100
Chicago, IL 60601
Tel.: (312) 456-1006
Fax: (312) 276-8548

In the United States Patent and Trademark Office

Application No.: 13/809,836 Filing Date: January 11, 2013
First Named Inventor: Shaojing HU Attorney Docket No.: 147028.010113
Title of Application: Novel Fused Heterocyclic Derivatives Useful as c-Met Tyrosine
Kinase Inhibitors

Commissioner for Patents
P.O. Box 1450
Alexandria, VA


DECLARATION

ZHEJIANG BETA PHARMA INC., an applicant and co-owner (co-assignee) of the above-referenced U.S. patent application, hereby states that its official name has been changed from "ZHEJIANG BETA PHARMA INC." to "BETTA PHARMACEUTICALS CO., LTD."

Respectively submitted

BETTA PHARMACEUTICALS CO., LTD

Date: NOV 25 2013

By:  /s/

Name: Shaojing Hu

Its: Vice President & Chief Chemist

变更登记情况

登记情况:

注册号: 330100400024187

企业名称: 贝达药业股份有限公司

住所(经营场所): 杭州市余杭经济技术开发区红丰路339号

法定代表人(负责人): 丁列明

企业类型: 股份有限公司(中外合资、未上市)

注册资本(资金数额): 15,000.0

万人民币元 登记机关: 杭州市工商行政管理局


经营起始日期: 2003/01/07

经营截至日期: 9999/09/09

核准日期: 2013/08/29

经营范围: 抗癌、抗心脑血管病新药的研究、开发、技术转让和技术咨询(国家禁止和限制的除外), 软膏剂、片剂的研制和生产

序号	变更事项	变更前内容	变更后内容	核准日期
17	名称变更	<p>企业名称: 浙江贝达药业有限公司; 注册资本: 5864.0626万人民币元; 实收资本: 5864.0626万人民币元; 企业类型: 有限责任公司(中外合资); 营业期限: 2003-1-7 至 2053-1-6; 执照有效期限: 2003-1-6 至 2053-1-6; 股东: 杭州金研睿成股权投资管理合伙企业(有限合伙), 113.2813万; 宁波美域股权投资合伙企业(有限合伙), 189.9219万; 成都先帝世纪医药健康创业投资有限公司, 179.5508万; Sequoia Capital China SP11(HK)Limited, 268.8061万; 杭州贝达投资管理合伙企业(有限合伙), 339.1796万; LAV Equity (Hong Kong) (C. Limited), 339.8438万; 浙江贝达投资管理合伙企业(有限合伙), 424.8047万; 贝达医药公司, 450.6831万; 宁波梅山保税港区特瑞西创投合伙企业(有限合伙), 608.0546万; 浙江祥和创业投资有限公司, 803.9819万; 宁波凯诺投资管理合伙企业(普通合伙), 1259.69万; Fenlai Tan, 67.9628万; HANCHENG ZHANG, 176.6788万; YINXIANG WANG, 308.0672万; 组织机构: YI SHI 职务: 董事; YINXIANG WANG (王翔宇) 职务: 董事兼总经理; Ying du 职务: 董事; 丁列明 职务: 董事长; 胡云彪 职务: 监事会主席; 董伟 职务: 监事; 王静方 职务: 监</p>	<p>企业名称: 贝达药业股份有限公司; 注册资本: 15000万人民币元; 实收资本: 15000万人民币元; 企业类型: 股份有限公司(中外合资、未上市); 营业期限: 2003-1-7 至 9999-9-9; 执照有效期限: 2003-1-6 至 9999-9-9; 股东: 杭州金研睿成股权投资管理合伙企业(有限合伙), 300万; 宁波美域股权投资合伙企业(有限合伙), 450万; 成都先帝世纪医药健康创业投资有限公司, 473.5万; Sequoia Capital China SP11(HK)Limited, 712.005万; 杭州贝达投资管理合伙企业(有限合伙), 885万; LAV Equity (Hong Kong) (C. Limited), 900万; 浙江贝达投资管理合伙企业(有限合伙), 1125万; 贝达医药公司, 1193.535万; 宁波梅山保税港区特瑞西创投合伙企业(有限合伙), 1605万; 浙江祥和创业投资有限公司, 2354万; 宁波凯诺投资管理合伙企业(普通合伙), 3336万; Fenlai Tan, 180万; HANCHENG ZHANG, 467.895万; YINXIANG WANG, 976.065万; 组织机构: Fenlai Tan 职务: 董事; YI SHI 职务: 董事; YINXIANG WANG 职务: 董事; Ying Du 职务: 董事; 蔡万裕 职务: 监事会主席; 丁列明 职务: 董事长兼总经理; 胡云彪 职务: 监事; 黄玲 职务: 监事; 李承光</p>	2013/08/29



打印日期: 2013/08/29 10:01:01